| 2026-10-26 16:47 |
8-K |
["8.01"] |
other |
0.05
|
Clinical trial results announcement for ATEBRIOZ; no M&A indicators present. |
SEC · detail |
| 2026-10-13 08:09 |
8-K |
["8.01"] |
other |
0.05
|
Routine 8-K announcing Phase 3 clinical trial results for LIVMARLI; no M&A signals. |
SEC · detail |
| 2026-09-28 08:02 |
8-K |
["8.01"] |
other |
0.05
|
FDA approval announcement and clinical trial results; no M&A signals detected. |
SEC · detail |
| 2026-09-08 08:34 |
8-K |
["5.02"] |
officer change |
0.15
|
Routine CMO replacement with standard severance; no M&A signals present. |
SEC · detail |
| 2026-08-05 16:02 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine 8-K reporting Q2 2026 financial results and corporate update; no M&A signals. |
SEC · detail |
| 2026-06-18 16:05 |
8-K |
["5.07"] |
other |
0.00
|
Routine 8-K filing reporting 2026 Annual Meeting stockholder votes on directors, auditor, and executive compensation. |
SEC · detail |
| 2026-05-18 16:06 |
8-K |
["1.01"] |
other |
0.05
|
Convertible note issuance for debt financing; no M&A signals or strategic transaction indicators present. |
SEC · detail |
| 2026-05-06 16:04 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine 8-K filing of Q1 2026 earnings results; no M&A signals detected. |
SEC · detail |
| 2026-05-04 08:00 |
8-K |
["8.01"] |
other |
0.05
|
Clinical trial results announcement for volixibat; no M&A or acquisition signals present. |
SEC · detail |
| 2026-04-27 08:07 |
8-K |
["8.01"] |
other |
0.05
|
Clinical trial results announcement for brelovitug; no M&A signals present. |
SEC · detail |